Results per Page:
Crunching the numbers for next-gen COVID-19 vaccines
BARDA taps Fred Hutch biostatisticians to assess new vaccine technology, more nimble trial design
Revaccination beliefs and behaviors in transplant survivors
From the UW School of Nursing in collaboration with the Long-Term Follow-Up Program, Clinical Research Division
¿Necesito otra vacuna de refuerzo contra el SRAS-CoV-2?
Del Dr. Bo Zhang y laboratorios colaboradores, División de Vacunas y Enfermedades Infecciosas
Surviving and thriving with metastatic breast cancer
From financial toxicity to sexual health, experts break down survival strategies for patients and caregivers dealing with ‘mets’
Do I need another SARS-CoV-2 booster vaccine?
From Dr. Bo Zhang and collaborating labs, Vaccine & Infectious Disease Division
Vaccine targets that accommodate evolving SARS-CoV-2 variants
From the Overbaugh Lab, Human Biology and Public Health Sciences Divisions
‘Black hole’ formed by aging cells hobbles key immune organ’s function, regeneration
Collaborative project reveals non-functional cells that accumulate in aging thymus
La eficacia de la vacuna contra el virus SARS-CoV-2 en países de América Latina
Del Grupo Gilbert, Divisiones de Vacunas y Enfermedades Infecciosas y de Ciencias de la Salud Pública
SARS-CoV-2 vaccine efficacy in Latin American countries
From the Gilbert Group, Vaccine and Infectious Disease and Public Health Sciences Divisions
Hard to swallow? RORγt expression in Tregs may not regulate oral tolerance, as previously hypothesized.
From the Kublin Lab, Vaccine and Infectious Disease Division
It takes two to tango in the brain
From Will Hannon and Dr. Alison Feder, Basic Sciences and Public Health Sciences Divisions
When it comes to HPV vaccination, just once is enough
Galloway Lab, Human Biology Division
Do our own bugs determine our response to vaccines? – Likely yes!
From the Kublin lab, Vaccine and Infectious Disease Division
Un ensayo clínico inicial destaca las vacunas contra el cáncer como posible tratamiento asequible, seguro y eficaz contra el cáncer de mama
Del Cancer Vaccine Institute [Instituto de Vacunas contra el Cáncer], la Universidad de Washington y del Cancer Consortium Breast & Ovary Cancers Program [Programa de Cáncer de Mama y Ovario del Consorcio del Cáncer].
Going long: Viruses linger with lasting impact
Herpes, HIV, Epstein-Barr and other viruses hang around, causing potential long-term health woes. Should ‘long COVID’ surprise us?
Is the microbiome a springboard or barrier to effective vaccination?
From the Kublin Lab, Vaccine and Infectious Disease Division
A win for vaccines: immune correlates identified for COVID-19
From the Fong, Gilbert, and collaborating labs, Vaccine and Infectious Disease Division & Public Health Sciences Division
A (literally) multi-pronged viral vaccine approach
From the McGuire Lab, Vaccine and Infectious Disease Division
COVID-19 complacency: ‘A hard shift for the immunocompromised’
Even with vaccines and antivirals, cancer patients and many others are still vulnerable to infection; some safety tips for this evolving pandemic